CD274 and non-small cell lung carcinoma: For example, a post hoc analysis of the POSEIDON trial evaluating combined PD-L1 and CTLA-4 inhibition with durvalumab and tremelimumab plus chemotherapy in metastatic NSCLC showed that patients with KEAP1, STK11, and KRAS mutations benefited more from combination immunotherapy [63].